What do systematic reviews say?

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.76, 1.35]
  2 studies · 340 participants
  Moderate

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: IMRT vs 3DCRT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Summary of findings: BT vs external beam radiotherapy (EBRT)

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 348 participants
  GRADE not reported

Summary of findings: Protein supplements vs no intervention

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Protein supplements vs no intervention

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Protein supplements vs no intervention

It is very uncertain whether summary of findings: Protein supplements changes diarrhoea (grade 2+) compared with no intervention (very low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.53 [0.27, 1.03]
  1 study · 74 participants
  Very low

Summary of findings: Protein supplements vs no intervention

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotics vs placebo or control

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotics vs placebo or control

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  HR 0.48 [0.22, 1.06]
  5 studies · 1388 participants
  Moderate

Intervention not reported

The intervention probably leads to lower relapse, progression or death (calculated instead of PFS)… (moderate certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  HR 0.24 [0.07, 0.88]
  900 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in infection‐ related mortality (low certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  RR 6.9 [0.36, 132.34]
  1 study · 276 participants
  Low

Intervention not reported

The intervention showed no clear difference in second cancer‐ related mortality (low certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  RR 2.22 [0.7, 7.03]
  1 study · 276 participants
  Low

Intervention not reported

The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  RR 0.99 [0.14, 6.9]
  1 study · 276 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  HR 0.31 [0.19, 0.52]
  3 studies · 816 participants
  Moderate

Intervention not reported

The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  HR 0.42 [0.25, 0.72]
  4 studies · 1351 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in infection‐ related mortality (low certainty).

• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 8.06]
  1 study · 152 participants
  Low